Preprint · CC-BY
via OpenAlex
Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
Miguel Martín‐Pérez, Takashi K. Ito, Anthony S. Grillo, Anthony S. Valente, Jeehae Han, Samuel W. Entwisle, Heather Z Huang, Dayae Kim, Masanao Yajima, Matt R. Kaeberlein, Judit Villén
bioRxiv (Cold Spring Harbor Laboratory) · 2019 · ▲ 5 citations
Deregulated nutrient-sensing
Mitochondrial dysfunction
Altered intercellular communication
Rapamycin / mTOR inhibition
Mouse
Abstract
Abstract Leigh syndrome is a fatal neurometabolic disorder caused by defects in mitochondrial function. mTOR(definition) inhibition with rapamycin(definition) attenuates disease progression in a mouse model of Leigh syndrome (Ndufs4 KO mouse); however, the mechanism of rescue is unknown. Here we assessed the impact of rapamycin on the brain proteome and phosphoproteome of Ndufs4 KO mice. We report that rapamycin remodels the brain proteome to alter mitochondrial structure, inhibits signaling through both mTOR complexes, and inhibits multiple protein kinase C (PKC) isoforms. Administration of PKC inhibitors was sufficient to increase survival, delay neurological deficits, and prevent hair loss in Ndufs4 KO mice. Thus, PKC may be a viable therapeutic target for treating severe mitochondrial disease. One Sentence Summary Proteomic and phosphoproteomic analysis of mouse brain identifies PKC as a key target to treat mitochondrial disease
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/562207
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Martín‐Pérez, M., Ito, T.K., Grillo, A.S., Valente, A.S., Han, J., Entwisle, S.W., Huang, H.Z., Kim, D., Yajima, M., Kaeberlein, M.R., & Villén, J. (2019). Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.1101/562207
Vancouver
Martín‐Pérez M, Ito TK, Grillo AS, Valente AS, Han J, Entwisle SW, et al. Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin. bioRxiv (Cold Spring Harbor Laboratory). 2019. doi:10.1101/562207.
BibTeX
@unpublished{miguel2019Protei,
title = {Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin},
author = {Miguel Martín‐Pérez and Takashi K. Ito and Anthony S. Grillo and Anthony S. Valente and Jeehae Han and Samuel W. Entwisle and Heather Z Huang and Dayae Kim and Masanao Yajima and Matt R. Kaeberlein and Judit Villén},
journal = {bioRxiv (Cold Spring Harbor Laboratory)},
year = {2019},
doi = {10.1101/562207},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Innovation in Aging 2020
Open access · CC-BY
Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh Syndrome
PLoS ONE 2011
Open access · CC-BY
Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
PLoS ONE 2011
Open access · CC-BY
Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
Neurobiology of Disease 2021
Open access · CC-BY
Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy
Nature Metabolism 2023
Preprint · CC-BY
Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh syndrome
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · CC-BY